multiple myeloma
Conditions
Interventions
Case series:No
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18to 75 years old, male or female; 2. Multiple myeloma patients receiving induction therapy and preparing for mobilization of stem cells for autologous transplantation, including patients who are initially treated and relapse-refractory; 3. ECOG10.0 g/L; (2) Urinary M protein >=200mg/24h; (3) Abnormal ? /? FLC ratio and involvement of free light chain (FLC) >=100 mg/L when serum free light chain was determined or no lesions were detected in serum or urine. 5, TBil <=2.0mg/dL, AST, ALT<=3.0xULN; 6. Informed Consent has been signed. Informed consent was signed by the patient himself or his immediate family. Considering the patient's condition, if the signature of the patient is not conducive to the treatment of the disease, the legal guardian or the patient's immediate family member should sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who are known to be allergic to bendamustine, melphalan or their excipients; 2. The patient has other tumors at the same time or a previous history of tumors; 3. Known patients with active hepatitis B virus or hepatitis C virus (HCV), or human immunodeficiency virus (HIV) serological positive; 4. Patients had uncontrolled or severe cardiovascular disease, including myocardial infarction within the first 6 months of enrolement, New York College of Cardiology (NYHA) defined iii-lead heart failure, uncontrolled angina pectoris, congestive heart failure, clinically significant pericardial disease, or cardiac amyloidosis (NT-pro-BNP >=1800pg/mL); 5. The patient is accompanied by severe infectious diseases; 6. According to the protocol or the investigator's judgment, the patient suffers from a serious physical or mental illness that may interfere with the participation in the clinical study; Substance abuse, medical, psychological, or social conditions that may interfere with subjects' participation in the study or evaluation of study results; 7. Patients receiving other experimental drug therapy; 8. Pregnant or lactating women; 9. Not suitable for participants considered by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;overall survival;minimal residual disease negative rate;security; | — |
Countries
China
Contacts
Public ContactLiu Zhigang
West China Hospital, Sichuan University
Outcome results
None listed